eToro said funded accounts rose 18% year over year to 4.39 million in Q3 2026 and announced a new $250 million share repurchase program. Its Q3 profit fell 74% to $15 million, primarily due to weaker cryptocurrency trading activity; earnings were $0.26 per share, below the Zacks consensus estimate of $0.34. Autolus Therapeutics reported AUCATZYL net product revenue of $41.2 million, up 95% year over year, and raised its 2026 revenue guidance to exceed the upper end of $150 million. Gilat Satellite reported earnings of $0.18 per share, above the $0.17 estimate but slightly below $0.19 a year earlier.
eToro reached 4.39 million funded accounts and launched a buyback program, while Autolus Therapeutics saw strong sales growth for its AUCATZYL product.
Read the full story